中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝星状细胞通过TGFβ1-PI3K/AKT信号通路影响肝硬化-肝细胞癌癌前病变的研究进展

鞠迪 李京涛 韩曼 魏海梁 闫曙光 李汨 史晓燕 常占杰

鞠迪, 李京涛, 韩曼, 魏海梁, 闫曙光, 李汨, 史晓燕, 常占杰. 肝星状细胞通过TGFβ1-PI3K/AKT信号通路影响肝硬化-肝细胞癌癌前病变的研究进展[J]. 临床肝胆病杂志, 2018, 34(1): 192-194. DOI: 10.3969/j.issn.1001-5256.2018.01.042.
引用本文: 鞠迪, 李京涛, 韩曼, 魏海梁, 闫曙光, 李汨, 史晓燕, 常占杰. 肝星状细胞通过TGFβ1-PI3K/AKT信号通路影响肝硬化-肝细胞癌癌前病变的研究进展[J]. 临床肝胆病杂志, 2018, 34(1): 192-194. DOI: 10.3969/j.issn.1001-5256.2018.01.042.
Ju Di, Li JingTao, Han Man, Wei HaiLiang, Yan ShuGuang, Li Mi, Shi XiaoYan, Chang ZhanJie. Research advances in the influence of hepatic stellate cells on precancerous lesions of liver cirrhosis and hepatocellular carcinoma via the TGFβ1-PI3K/AKT signaling pathway[J]. J Clin Hepatol, 2018, 34(1): 192-194. DOI: 10.3969/j.issn.1001-5256.2018.01.042.
Citation: Ju Di, Li JingTao, Han Man, Wei HaiLiang, Yan ShuGuang, Li Mi, Shi XiaoYan, Chang ZhanJie. Research advances in the influence of hepatic stellate cells on precancerous lesions of liver cirrhosis and hepatocellular carcinoma via the TGFβ1-PI3K/AKT signaling pathway[J]. J Clin Hepatol, 2018, 34(1): 192-194. DOI: 10.3969/j.issn.1001-5256.2018.01.042.

肝星状细胞通过TGFβ1-PI3K/AKT信号通路影响肝硬化-肝细胞癌癌前病变的研究进展

DOI: 10.3969/j.issn.1001-5256.2018.01.042
基金项目: 

国家自然科学基金(81603612); 陕西省科技厅(2012SF2-11,2014K11-02-04-06,2016SF-234); 陕西省中医药管理局(15-JC009,JCPT037); 北京医学奖励基金会课题(YJHYXKYJJ-276); 陕西中医药大学自然科学创新基金项目(2017SZKY-037); 

详细信息
  • 中图分类号: R575.2;R735.7

Research advances in the influence of hepatic stellate cells on precancerous lesions of liver cirrhosis and hepatocellular carcinoma via the TGFβ1-PI3K/AKT signaling pathway

Research funding: 

 

  • 摘要:

    肝硬化-肝细胞癌癌前病变的恶性转变导致肝癌的形成。肝星状细胞(HSC)通过TGFβ1-PI3K/AKT信号通路影响肝细胞癌癌前病变细胞产生、肝纤维化微环境的形成以及两者相互作用。了解肝硬化-肝细胞癌癌前病变的恶变机制与HSC和TGFβ1-PI3K/AKT信号通路的关系,将有助于深入了解肝细胞癌的发生机制。通过调控HSC或干预TGFβ1-PI3K/AKT信号通路可阻止甚至或逆转肝硬化向肝细胞癌的进展,为预防和干预肝细胞癌发生提供新的思路和治疗靶点。

     

  • [1]VENOOK AP, PAPANDREOU C, FURUSE J, et al.The incidence and epidemiology of hepatocellular carcinoma:a global and regional perspective[J].Oncologist, 2010, 15 Suppl 4:5-13.
    [2]GATENBY RA.A change of strategy in the war on cancer[J].Nature, 2009, 459 (7246) :508-509.
    [3]LI Y, ZHANG Z, SHI J, et al.Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBVassociated liver cirrhosis in China[J].Int J Clin Exp Med, 2015, 8 (1) :1205-1212.
    [4]KEW MC.The role of cirrhosis in the etiology of hepatocellular carcinoma[J].J Gastrointest Cancer, 2014, 45 (1) :12-21.
    [5]JIAO JZ, LI JT, YAN SG, et al.Current research status of precancerous dysplastic nodules in hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (5) :974-978. (in Chinese) 焦俊喆, 李京涛, 闫曙光, 等.肝细胞癌癌前异型增生结节的研究现状[J].临床肝胆病杂志, 2017, 33 (5) :974-978.
    [6]ZHANG L, ZHOU F, TEN DIJKE P.Signaling interplay between transforming growth factor-βreceptor and PI3K/AKT pathways in cancer[J].Trends Biochem Sci, 2013, 38 (12) :612-620.
    [7]ZHOU Q, LUI VW, YEO W.Targeting the PI3K/Akt/m TOR pathway in hepatocellular carcinoma[J].Future Oncol, 2011, 7 (10) :1149-1167.
    [8]MORMONE E, GEORGE J, NIETO N.Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches[J].Chem Biol Interact, 2011, 193 (3) :225-231.
    [9]WHITTAKER S, MARAIS R, ZHU AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma[J].Oncogene, 2010, 29 (36) :4989-5005.
    [10]COULOUARN C, CORLU A, GLAISE D, et al.Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma[J].Cancer Res, 2012, 72 (10) :2533-2542.
    [11]SANTAMATO A, FRANSVEA E, DITURI F, et al.Hepatic stellate cells stimulate HCC cell migration via laminin-5 production[J].Clin Sci (Lond) , 2011, 121 (4) :159-168.
    [12]HERNANDEZ-GEA V, TOFFANIN S, FRIEDMAN SL, et al.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma[J].Gastroenterology, 2013, 144 (3) :512-527.
    [13]THOMPSON AI, CONROY KP, HENDERSON NC.Hepatic stellate cells:central modulators of hepatic carcinogenesis[J].BMC Gastroenterol, 2015, 15:63.
    [14]SONG Y, KIM SH, KIM KM, et al.Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids[J].Sci Rep, 2016, 6:36750.
    [15]WANG X, HASSAN W, JABEEN Q, et al.Interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma[J].Cytokine, 2017.[Epub ahead of print]
    [16]TAHMASEBI BIRGANI M, CARLONI V.Tumor microenvironment, a paradigm in hepatocellular carcinoma progression and therapy[J].Int J Mol Sci, 2017, 18 (2) :405.
    [17]XIA YH, LU Z, ZHAO M, et al.Tumor-specific hepatic stellate cells (t HSCs) induces DIgR2 expression in dendritic cells to inhibit T cells[J].Oncotarget, 2017, 8 (33) :55084-55093.
    [18]WU K, DING J, CHEN C, et al.Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development[J].Hepatology, 2012, 56 (6) :2255-2267.
    [19]KATZ LH, LI Y, CHEN JS, et al.Targeting TGF-βsignaling in cancer[J].Expert Opin Ther Targets, 2013, 17 (7) :743-760.
    [20]GUPTA DK, SINGH N, SAHU DK.TGF-βmediated crosstalk between malignant hepatocyte and tumor microenvironment in hepatocellular carcinoma[J].Cancer Growth Metastasis, 2014, 7:1-8.
    [21]YOSHIDA K, MURATA M, YAMAGUCHI T, et al.Reversible human TGF-βsignal shifting between tumor suppression and fibro-carcinogenesis:implications of smad phospho-isoforms for hepatic epithelial-mesenchymal transitions[J].J Clin Med, 2016, 5 (1) .pii:E7.
    [22]ZHU HB, YANG YS, GUO MZ.Transforming growth factorβ (TGF-β) and hepatocellular carcinoma[J].Chin J Gastroenterol Hepatol, 2012, 21 (3) :206-209. (in Chinese) 朱宏斌, 杨云生, 郭明洲.肝癌中转化生长因子 (TGF) -β信号转导通路的研究进展[J].胃肠病学和肝病学杂志, 2012, 21 (3) :206-209.
    [23]COULOUARN C, CLEMENT B.Stellate cells and the development of liver cancer:therapeutic potential of targeting the stroma[J].J Hepatol, 2014, 60 (6) :1306-1309.
    [24]YOSHIDA K, MURATA M, YAMAGUCHI T, et al.TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review) [J].Int J Oncol, 2014, 45 (4) :1363-1371.
    [25]ARRESE M, CABRERA D, HERNANDEZ A, et al.TGF-βand hepatocellular carcinoma:when a friend becomes an enemy[J].Curr Protein Pept Sci, 2017.[Epub ahead of print]
    [26]ZHANG YE.Non-Smad pathways in TGF-beta signaling[J].Cell Res, 2009, 19 (1) :128-139.
    [27]SPANGLE JM, ROBERTS TM, ZHAO JJ.The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer[J].Biochim Biophys Acta, 2017, 1868 (1) :123-131.
    [28]JOSHI S, SINGH AR, DURDEN DL.Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma[J].Cancer Chemother Pharmacol, 2015, 75 (3) :595-608.
    [29]SINGH AR, JOSHI S, BURGOYNE AM, et al.Single agent and synergistic activity of the"first-in-class"dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma[J].Mol Cancer Ther, 2016, 15 (11) :2553-2562.
    [30]GULHATI P, BOWEN KA, LIU J, et al.m TORC1 and m TORC2 regulate EMT, motility, and metastasis of colorectal cancer via Rho A and Rac1 signaling pathways[J].Cancer Res, 2011, 71 (9) :3246-3256.
  • 加载中
计量
  • 文章访问数:  2140
  • HTML全文浏览量:  62
  • PDF下载量:  398
  • 被引次数: 0
出版历程
  • 出版日期:  2018-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回